×
About 198,445 results

Lower bevacizumab doses, agents with less systemic exposure may be safer options for ROP
https://www.healio.com/news/ophthalmology/20220203/lower-bevacizumab-doses-agents-with-less-systemic-exposure-may-be-safer-options-for-rop

Feb 3rd, 2022 - WAIKOLOA, Hawaii — Systemic effects of anti-VEGF in retinopathy of prematurity have not been ruled out, so it may be wise to use bevacizumab in lower doses or switch to agents with less systemic exposure, according to one presenter. “The BEAT-ROP study demonstrated a beneficial effect for bevacizumab vs. laser in the treatment of zone I, stage 3+ ROP. But one thing I didn’t like was the complet...

Remission From Type 2 Diabetes: Myth or Reality?
https://www.medscape.com/viewarticle/985111

Dec 6th, 2022 - Stockholm, Sweden — Because half of patients with type 2 diabetes (T2D) in France have blood glucose levels that are outside of their target range, the idea of remission from the condition is not at the forefront of doctors' minds. It takes second place to glycemic control. Yet, an international consensus suggests that modern-day medicines now make remission possible in those recently diagnosed...

The state-of-the-art pharmacotherapeutic management of neovascular age-related macular ...
https://doi.org/10.1080/14656566.2022.2154145
Expert Opinion on Pharmacotherapy; Servillo A, Zucchiatti I et. al.

Dec 6th, 2022 - Age-related macular degeneration (AMD) is a major cause of central visual loss in the developed world. Although the pathogenesis is not fully understood, vascular endothelial growth factor (VEGF) is considered the most important growth factor involved in angiogenesis and exudation in neovascular AMD eyes. Advances in anti-VEGF agents have changed the treatment approach for wet AMD, allowing bet...

Retreatment with anti-tumor necrosis factor therapy in combination with an immunomodula...
https://doi.org/10.1097/MEG.0000000000002474
European Journal of Gastroenterology & Hepatology; Ten Bokkel Huinink S, Beelen EMJ et. al.

Dec 6th, 2022 - A considerable proportion of Crohn's disease patients that undergo ileocecal resection (ICR) have failed anti-tumor necrosis factor (TNF) therapy preoperatively. This study aimed to assess the effectiveness of retreatment of anti-TNF therapy in patients with postoperative recurrence. A real-world cohort study was performed on Crohn's disease patients who underwent primary ICR after anti-TNF the...

A novel tumor-promoting role for nuclear factor IX in glioblastoma is mediated through ...
https://doi.org/10.1158/1541-7786.MCR-22-0504
Molecular Cancer Research : MCR; Ge R, Wang C et. al.

Dec 6th, 2022 - Our previous study illustrated that nuclear factor IX (NFIX) promotes glioblastoma (GBM) progression by inducing migration and proliferation of GBM cells. However, the underlying mechanism of how NFIX regulates GBM cell proliferation remains obscure. In this study, we uncovered that Go-Ichi-Ni-San 1 (GINS1) is up-regulated and positively correlated with NFIX in human GBM specimen. NFIX silencin...

A new series of thiazole-hydrazone hybrids for Akt-targeted therapy of non-small cell l...
https://doi.org/10.1002/ddr.22022
Drug Development Research; Orujova T, Ece A et. al.

Dec 6th, 2022 - In an attempt to identify potent antitumor agents for the fight against non-small cell lung cancer, new thiazolyl hydrazones (2a-n) were synthesized and examined for their in vitro cytotoxic effects on A549 human lung adenocarcinoma and L929 mouse embryonic fibroblast cells by means of the MTT assay. Furthermore, the effects of the most potent anticancer agents on apoptosis and Akt inhibition w...

Dendritic cell vaccines improve the glioma microenvironment: Influence, challenges, and...
https://doi.org/10.1002/cam4.5511
Cancer Medicine; Zhou J, Li L et. al.

Dec 6th, 2022 - Gliomas, especially the glioblastomas, are one of the most aggressive intracranial tumors with poor prognosis. This might be explained by the heterogeneity of tumor cells and the inhibitory immunological microenvironment. Dendritic cells (DCs), as the most potent in vivo functional antigen-presenting cells, link innate immunity with adaptive immunity. However, their function is suppressed in gl...

Adverse events associated with intra-arterial administration of gadolinium-based contra...
https://doi.org/10.1016/j.jvir.2022.11.022
Journal of Vascular and Interventional Radiology : JVIR; MacLeod CA, Gauthier I et. al.

Dec 5th, 2022 - To determine the risk of immediate hypersensitivity reactions (HRs), contrast-associated acute kidney injury (CA-AKI), nephrogenic systemic fibrosis (NSF), and gadolinium retention associated with use of intra-arterial gadolinium-based contrast agents (GBCA). MEDLINE, EMBASE, and Cochrane Central Register of Controlled Trials (CENTRAL) were searched from 1988 (GBCA approved for clinical use) to...

Vitiligo: An immune disease and its emerging mesenchymal stem cell therapy paradigm.
https://doi.org/10.1016/j.trim.2022.101766
Transplant Immunology; Zhang M, Xia T et. al.

Dec 5th, 2022 - Melanocyte damage, innate immune response, adaptive immune response, and immune inflammatory microenvironment disorders are involved in the development of the immunological pathogenic mechanism of vitiligo. Mesenchymal stem cells are considered an ideal type of cells for the treatment of vitiligo owing to their low immunogenicity, lower rates of transplant rejection, and ability to secrete nume...

Posterior reversible encephalopathy syndrome and autoimmunity.
https://doi.org/10.1016/j.autrev.2022.103239
Autoimmunity Reviews; Li Y, Song J et. al.

Dec 5th, 2022 - Posterior reversible encephalopathy syndrome (PRES) is a clinical syndrome characterized by acute or subacute onset of neurological symptoms (e.g., headache, seizure, confusion, vomiting, and diminished eyesight) and impaired endothelial barrier function of the cerebral circulation that leads to bilateral subcortical vasogenic edema, while exhibiting a "reversible" feature in most cases. Clinic...

Detection of parasite-derived tRNA and rRNA fragments in the peripheral blood of mice e...
https://doi.org/10.1016/j.parint.2022.102716
Parasitology International; Kusakisako K, Nakao R et. al.

Dec 5th, 2022 - All prokaryotes and eukaryotes, including parasites, release extracellular vesicles or exosomes that contain selected proteins, lipids, nucleic acids, glycoconjugates, and metabolites. Leishmania exosomes are highly enriched in small RNAs derived from the rRNAs and tRNAs of the protozoan parasite species. Here, using plasma exosomes isolated by a kit and next-generation sequencing, we report th...

The emerging therapeutic landscape of relapsed/refractory multiple myeloma.
https://doi.org/10.1007/s00277-022-05058-5
Annals of Hematology; Tanenbaum B, Miett T et. al.

Dec 4th, 2022 - From a historic lens, treatment for patients with relapsed/refractory multiple myeloma (R/R MM) has advanced significantly since the advent of immunomodulatory agents (IMiDs) in the 1990s, proteasome inhibitors in the 2000s, monoclonal antibodies in the 2010s, and CAR-T treatments in the 2020s. However, the availability of multiple new therapies has also created significant ambiguity regarding ...

High-content drug screening in zebrafish xenografts reveals high efficacy of dual MCL-1...
https://doi.org/10.1016/j.canlet.2022.216028
Cancer Letters; Grissenberger S, Sturtzel C et. al.

Dec 4th, 2022 - Ewing sarcoma is a pediatric bone and soft tissue cancer with an urgent need for new therapies to improve disease outcome. To identify effective drugs, phenotypic drug screening has proven to be a powerful method, but achievable throughput in mouse xenografts, the preclinical Ewing sarcoma standard model, is limited. Here, we explored the use of xenografts in zebrafish for high-throughput drug ...

Activation of cannabinoid-2 receptor protects against Pseudomonas aeruginosa induced ac...
https://doi.org/10.1186/s12931-022-02253-w
Respiratory Research; Nagre N, Nicholson G et. al.

Dec 4th, 2022 - Bacterial pneumonia is a major risk factor for acute lung injury (ALI) and acute respiratory distress syndrome (ARDS). Pseudomonas aeruginosa (PA), an opportunistic pathogen with an increasing resistance acquired against multiple drugs, is one of the main causative agents of ALI and ARDS in diverse clinical settings. Given the anti-inflammatory role of the cannabinoid-2 receptor (CB2R), the eff...

Chloroquine treatment influences immunologicalmemory through the PD-1/PD-L1 pathway dur...
https://doi.org/10.1016/j.intimp.2022.109403
International Immunopharmacology; Peng C, Li D et. al.

Dec 4th, 2022 - Growing evidence describes the host immune response mechanism involved in malaria. Despite the spread of drug resistance, chloroquine (CQ) remains the main antimalarial drug in most countries in Latin America and Asia. Studies have indicated an immunomodulatory activity of CQ, however, the potential implications for CQ on immunological memory recognizing the malaria parasite are still being elu...

Cytokines network in primary membranous nephropathy.
https://doi.org/10.1016/j.intimp.2022.109412
International Immunopharmacology; Zhao Q, Dai H et. al.

Dec 4th, 2022 - There have been extensive studies on the immunological mechanism of primary membranous nephropathy (PMN). Autoantibodies, being the end product of humoral auto-immunity, matter much in diagnosis, therapy and prediction. Although PMN has been thought of as oligoinflammatory glomerulopathy, autoimmune diseases usually involve inflammation and it may be long-lasting. Cytokines are key mediators an...

A retrospective study of cladribine and low-dose cytarabine-based regimens for the trea...
https://doi.org/10.1002/cncr.34564
Cancer Bazinet A, Darbaniyan F et. al.

Dec 3rd, 2022 - Patients with higher risk chronic myelomonocytic leukemia (CMML) have limited therapeutic options beyond hydroxyurea and hypomethylating agents (HMAs). Regimens based on a backbone of cladribine (CLAD), low-dose cytarabine (LDAC), and an HMA are effective low-intensity therapies for acute myeloid leukemia (AML). The authors conducted a retrospective chart review to evaluate the efficacy of CLAD...

Optimizing targeted drug selection in combination therapy for patients with advanced or...
https://doi.org/10.1002/cam4.5504
Cancer Medicine; Xie R, Wu J et. al.

Dec 3rd, 2022 - For patients with advanced or metastatic renal cell carcinoma (RCC), the dose of targeted agents was recommended in combination with immune checkpoint inhibitors. We performed a network meta-analysis to describe a categorized safety ranking profile and assess the adaptability of the combination options of targeted agents. The targeted agents refer to vascular endothelial growth factor tyrosine ...

Cancer screening and prevention education in standardized training residents: A cross-s...
https://doi.org/10.1186/s12909-022-03876-9
BMC Medical Education; Ran J, Dai Z et. al.

Dec 3rd, 2022 - Standardized residency training is an essential aspect of enhancing the ability of cancer prevention and screening of residents. The current study was performed to investigate tumor prevention, screening literacy and the training demands of standardized training residents and explore related influencing factors. A cross-sectional survey was conducted among 320 residents of The First Hospital of...

Proinflammatory activity of VEGF-targeted treatment through reversal of tumor endotheli...
https://doi.org/10.1007/s10456-022-09863-4
Angiogenesis Nowak-Sliwinska P, van Beijnum JR et. al.

Dec 3rd, 2022 - Ongoing angiogenesis renders the tumor endothelium unresponsive to inflammatory cytokines and interferes with adhesion of leukocytes, resulting in escape from immunity. This process is referred to as tumor endothelial cell anergy. We aimed to investigate whether anti-angiogenic agents can overcome endothelial cell anergy and provide pro-inflammatory conditions. Tissues of renal cell carcinoma (...